

List of Publications by Citations

Source: <https://exaly.com/author-pdf/224551/j-jack-lee-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

478 papers	38,623 citations	98 h-index	183 g-index
511 ext. papers	45,192 ext. citations	6.9 avg, IF	7.51 L-index

#	Paper	IF	Citations
478	Comprehensive genomic characterization of head and neck squamous cell carcinomas. <i>Nature</i> , 2015 , 517, 576-82	50.4	2332
477	Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002 , 53, 1097-105	4	1132
476	Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. <i>Nature</i> , 2017 , 546, 498-503	50.4	1093
475	Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. <i>Journal of Clinical Oncology</i> , 1999 , 17, 976-83	2.2	1039
474	The BATTLE trial: personalizing therapy for lung cancer. <i>Cancer Discovery</i> , 2011 , 1, 44-53	24.4	660
473	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. <i>Science</i> , 2014 , 346, 256-9	33.3	659
472	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. <i>Clinical Cancer Research</i> , 2013 , 19, 279-90	12.9	649
471	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018 , 8, 822-835	24.4	648
470	Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. <i>Nature Medicine</i> , 1996 , 2, 985-91	50.5	615
469	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. <i>Lancet Oncology</i> , 2016 , 17, 1672-1682	21.7	548
468	Dose escalation methods in phase I cancer clinical trials. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 708-20	9.7	528
467	Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2544-55	2.2	497
466	Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2253-60	2.2	478
465	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1558-1565	2.2	445
464	Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 763-71	9.7	432
463	Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3904-11	2.2	423
462	Surgical treatment of multiple brain metastases. <i>Journal of Neurosurgery</i> , 1993 , 79, 210-6	3.2	392

461	Mutational landscape of aggressive cutaneous squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 6582-92	12.9	362
460	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. <i>Journal of Clinical Oncology</i> , 2012 , 30, 777-82	2.2	355
459	Clonal genetic alterations in the lungs of current and former smokers. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 857-62	9.7	342
458	Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. <i>New England Journal of Medicine</i> , 1995 , 332, 1405-10	59.2	339
457	Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 228-39	9.7	331
456	Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. <i>New England Journal of Medicine</i> , 1993 , 328, 15-20	59.2	326
455	Mortality risk from squamous cell skin cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 759-65	2.2	322
454	Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2164-70	2.2	314
453	Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2045-52	2.2	313
452	Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2000 , 18, 609-22	2.2	297
451	Quality of life assessment. An independent prognostic variable for survival in lung cancer. <i>Cancer</i> , 1991 , 67, 3131-5	6.4	295
450	Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3817-25	2.2	286
449	Predicting cancer development in oral leukoplakia: ten years of translational research. <i>Clinical Cancer Research</i> , 2000 , 6, 1702-10	12.9	276
448	Quality of life in adult survivors of lung, colon and prostate cancer. <i>Quality of Life Research</i> , 1994 , 3, 127-41	3.7	274
447	Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 605-18	9.7	267
446	Breast conservation versus mastectomy. Is there a difference in psychological adjustment or quality of life in the year after surgery?. <i>Cancer</i> , 1992 , 69, 1729-38	6.4	265
445	Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. <i>Cancer</i> , 2006 , 107, 563-9	6.4	246
444	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. <i>Nature Medicine</i> , 2019 , 25, 744-750	50.5	240

443	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer—a plan to move forward. <i>Clinical Cancer Research</i> , 2006 , 12, 3661-97	12.9	235
442	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. <i>Cancer Research</i> , 2013 , 73, 276-84	10.1	221
441	Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1511-6	9.7	217
440	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 67-73	13.4	217
439	Bayesian Adaptive Methods for Clinical Trials		206
438	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. <i>Nature Medicine</i> , 2019 , 25, 751-758	50.5	205
437	Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. <i>Laryngoscope</i> , 2005 , 115, 1561-7	3.6	205
436	The CARES: a generic measure of health-related quality of life for patients with cancer. <i>Quality of Life Research</i> , 1992 , 1, 19-29	3.7	202
435	Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 744-51	2.2	196
434	Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 8-14	2.2	191
433	Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. <i>JAMA Oncology</i> , 2016 , 2, 1452-1459	13.4	190
432	Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 441-50	9.7	188
431	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. <i>Cell Reports</i> , 2014 , 6, 377-87	10.6	186
430	Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. <i>Cancer Prevention Research</i> , 2009 , 2, 931-41	3.2	182
429	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in -Mutant NSCLC. <i>Clinical Cancer Research</i> , 2018 , 24, 6195-6203	13.9	178
428	A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. <i>Lung Cancer</i> , 2003 , 39, 55-61	5.9	173
427	Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. <i>Surgery</i> , 1998 , 124, 203-210	3.6	168
426	Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 825-32	8.9	167

425	Is follow-up of lung cancer patients after resection medically indicated and cost-effective?. <i>Annals of Thoracic Surgery</i> , 1995 , 60, 1563-70; discussion 1570-2	2.7	167
424	Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. <i>Cancer</i> , 2006 , 107, 2637-46	6.4	164
423	Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 624-9	9.7	163
422	Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 354-60	2.2	157
421	Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. <i>Journal of Clinical Oncology</i> , 1994 , 12, 937-45	2.2	157
420	Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1813-1822	2.2	156
419	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3077-83	2.2	154
418	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016 , 76, 3690-701	10.1	154
417	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. <i>PLoS ONE</i> , 2011 , 6, e22769	3.7	153
416	Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. <i>Clinical Trials</i> , 2008 , 5, 181-93	2.2	149
415	p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. <i>Journal of the National Cancer Institute</i> , 1996 , 88, 519-29	9.7	149
414	Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. <i>Clinical Cancer Research</i> , 2003 , 9, 93-101	12.9	146
413	Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2509-15	2.2	142
412	Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. <i>Cancer Prevention Research</i> , 2012 , 5, 1081-9	3.2	132
411	Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. <i>Clinical Cancer Research</i> , 2009 , 15, 5359-68	12.9	131
410	Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. <i>Journal of Clinical Oncology</i> , 1995 , 13, 1893-903	2.2	130
409	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis. <i>Radiotherapy and Oncology</i> , 2016 , 120, 48-55	5.3	129
408	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2017 , 112, 90-95	5.9	128

407	Objective detection and delineation of oral neoplasia using autofluorescence imaging. <i>Cancer Prevention Research</i> , 2009 , 2, 423-31	3.2	128
406	Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 1545-51	9.7	126
405	Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. <i>Carcinogenesis</i> , 2005 , 26, 1368-73	4.6	124
404	Cancer chemoprevention: progress and promise. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 1514-38	9.7	124
403	Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 193-201	2.2	123
402	Second primary tumors in patients with upper aerodigestive tract cancers: joint effects of smoking and alcohol (United States). <i>Cancer Causes and Control</i> , 2003 , 14, 131-8	2.8	123
401	15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1136-42	9.7	121
400	Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2006 , 106, 2428-36	6.4	120
399	Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. <i>PLoS ONE</i> , 2012 , 7, e34833	3.7	119
398	CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. <i>Cancer Research</i> , 2013 , 73, 571-82	10.1	114
397	Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 364-70	2.2	113
396	Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. <i>Clinical Cancer Research</i> , 2004 , 10, 1733-42	12.9	111
395	Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , 2020 , 6, 375-384	13.4	110
394	Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 1962-72	6.1	109
393	Nonparametric Regression Analysis of Longitudinal Data. <i>Journal of the American Statistical Association</i> , 1998 , 93, 1403-1418	2.8	109
392	Randomized phase II designs in cancer clinical trials: current status and future directions. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4450-7	2.2	108
391	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3638-3647	2.2	108
390	Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	106

389	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017 , 7, 1088-1097	24.4	105
388	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021 , 27, 504-514	50.5	105
387	Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. <i>Journal of Clinical Oncology</i> , 2017 , 35, 352-360	2.2	104
386	EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. <i>Clinical Cancer Research</i> , 2013 , 19, 6556-65	12.9	103
385	Interaction index and different methods for determining drug interaction in combination therapy. <i>Journal of Biopharmaceutical Statistics</i> , 2007 , 17, 461-80	1.3	103
384	A predictive probability design for phase II cancer clinical trials. <i>Clinical Trials</i> , 2008 , 5, 93-106	2.2	102
383	Transforming Cancer Prevention through Precision Medicine and Immune-oncology. <i>Cancer Prevention Research</i> , 2016 , 9, 2-10	3.2	101
382	Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. <i>Cancer</i> , 2004 , 101, 2837-42	6.4	101
381	Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 1998 , 16, 1325-30	2.2	101
380	Bayesian clinical trials in action. <i>Statistics in Medicine</i> , 2012 , 31, 2955-72	2.3	98
379	The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. <i>Annals of Thoracic Surgery</i> , 2003 , 76, 1001-7; discussion 1007-8	2.7	97
378	Akt activation correlates with adverse outcome in tongue cancer. <i>Cancer</i> , 2005 , 104, 2430-6	6.4	97
377	Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. <i>Journal of Clinical Oncology</i> , 1996 , 14, 503-13	2.2	97
376	Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 6278-6289	12.9	96
375	ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 3383-95	12.9	96
374	Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. <i>Clinical Cancer Research</i> , 2010 , 16, 1289-97	12.9	96
373	Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. <i>Cancer Prevention Research</i> , 2010 , 3, 800-9	3.2	96
372	Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 6014-22	12.9	96

371	Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3230-7	2.2	96
370	Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 682-90	8.9	95
369	Gene expression profiling predicts the development of oral cancer. <i>Cancer Prevention Research</i> , 2011 , 4, 218-29	3.2	95
368	Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. <i>Chest</i> , 2009 , 136, 701-709	5.3	91
367	Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 209-16	13.4	89
366	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 1107-14	4	88
365	Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. <i>JCI Insight</i> , 2020 , 5,	9.9	88
364	High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 833-40	8.9	87
363	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. <i>Oncotarget</i> , 2013 , 4, 705-14	3.3	87
362	Genomic heterogeneity of multiple synchronous lung cancer. <i>Nature Communications</i> , 2016 , 7, 13200	17.4	85
361	Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 599-604	2.2	85
360	Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. <i>Clinical Trials</i> , 2009 , 6, 205-16	2.2	85
359	Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1668-82	9.7	85
358	Exploring the influence of multiple variables on the relationship of age to quality of life in women with breast cancer. <i>Journal of Clinical Epidemiology</i> , 1992 , 45, 473-85	5.7	85
357	Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. <i>Cancer Research</i> , 2002 , 62, 351-5	10.1	85
356	Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 198-205	9.7	84
355	Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 1995 , 13, 2361-8	2.2	83
354	Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. <i>Journal of Clinical Oncology</i> , 1996 , 14, 287-95	2.2	83

353	Accuracy of in vivo multimodal optical imaging for detection of oral neoplasia. <i>Cancer Prevention Research</i> , 2012 , 5, 801-9	3.2	82
352	Long-term impact of smoking on lung epithelial proliferation in current and former smokers. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1081-8	9.7	82
351	Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. <i>Journal of Clinical Oncology</i> , 1997 , 15, 2826-31	2.2	81
350	Pilot randomized phase II study of celecoxib in oral premalignant lesions. <i>Clinical Cancer Research</i> , 2008 , 14, 2095-101	12.9	81
349	The influence of resection and aneuploidy on mortality in oral leukoplakia. <i>New England Journal of Medicine</i> , 2004 , 350, 1405-13	59.2	81
348	Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. <i>Cancer</i> , 2009 , 115, 1669-79	6.4	80
347	Genetic variation in MicroRNA genes and risk of oral premalignant lesions. <i>Molecular Carcinogenesis</i> , 2010 , 49, 183-9	5	80
346	Bayesian adaptive randomization designs for targeted agent development. <i>Clinical Trials</i> , 2010 , 7, 584-96.2		79
345	Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2798-804	2.2	78
344	Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 6119-25	12.9	77
343	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches 2018 , 6, 48		76
342	Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 257-8	9.7	76
341	Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. <i>Cancer</i> , 2012 , 118, 2889-99	6.4	75
340	Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 206-14	9.7	75
339	DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. <i>Clinical Cancer Research</i> , 2011 , 17, 2035-43	12.9	74
338	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. <i>Nature Communications</i> , 2018 , 9, 3114	17.4	73
337	The incidence of second primary tumors in long-term survivors of small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 1992 , 10, 1519-24	2.2	73
336	Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 222-8	8.9	72

335	Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 436-42	8.9	72
334	Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2684-90	2.2	71
333	PIK3CA mutations in advanced cancers: characteristics and outcomes. <i>Oncotarget</i> , 2012 , 3, 1566-75	3.3	71
332	Tissue platinum concentration and tumor response in non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3345-52	2.2	69
331	Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. <i>Cancer Prevention Research</i> , 2008 , 1, 39-44	3.2	69
330	Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1974-8	2.2	69
329	Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. <i>Cancer Research</i> , 2016 , 76, 675-85	10.1	68
328	Phase II study of gefitinib in patients with advanced salivary gland cancers. <i>Head and Neck</i> , 2015 , 37, 644-9	4.2	67
327	Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. <i>PLoS ONE</i> , 2011 , 6, e21428	3.7	67
326	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020 , 11, 603	17.4	67
325	Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. <i>Oncogene</i> , 2010 , 29, 2616-27	9.2	66
324	Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 1317-21	9.7	66
323	Abnormalities of the TTF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. <i>Clinical Cancer Research</i> , 2011 , 17, 2434-43	12.9	65
322	Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. <i>Melanoma Research</i> , 1998 , 8, 549-56	3.3	65
321	Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. <i>Cancer</i> , 2001 , 91, 1316-23	6.4	64
320	Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. <i>Annals of Oncology</i> , 2017 , 28, 83-89	10.3	63
319	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Eblockers. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	62
318	Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3597-603	2.2	62

317	Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. <i>Cancer Prevention Research</i> , 2008 , 1, 112-8	3.2	61
316	Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. <i>Cancer</i> , 2018 , 124, 2169-2173	6.4	60
315	Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). <i>Cancer Gene Therapy</i> , 2000 , 7, 530-6	5.4	59
314	Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. <i>Annals of Oncology</i> , 2015 , 26, 1791-8 ^{10.3}	10.3	58
313	Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2015 , 26, 1476-80	10.3	57
312	Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 859-65	9.7	57
311	A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis. <i>Clinical Cancer Research</i> , 2011 , 17, 1490-501	12.9	55
310	p53 and retinoid chemoprevention of oral carcinogenesis. <i>Cancer Research</i> , 1995 , 55, 16-9	10.1	55
309	Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4163-9	2.2	54
308	Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 1393-9	9.7	53
307	DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. <i>Clinical Cancer Research</i> , 2009 , 15, 6284-91	12.9	52
306	Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. <i>Cancer Prevention Research</i> , 2009 , 2, 617-24	3.2	52
305	Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. <i>Cancer</i> , 2012 , 118, 2454-65	6.4	51
304	Expression of Delta DNMT3B variants and its association with promoter methylation of p16 and RASSF1A in primary non-small cell lung cancer. <i>Cancer Research</i> , 2006 , 66, 8361-6	10.1	51
303	Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 782-90	4	50
302	Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. <i>Annals of Surgical Oncology</i> , 2009 , 16, 2181-7	3.1	50
301	Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. <i>Cancer</i> , 2008 , 112, 1058-65	6.4	50
300	Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 364-370	2.2	50

299	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. <i>Oncotarget</i> , 2014 , 5, 2349-54	3.3	50
298	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2475-2485	6.1	49
297	Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. <i>Clinical Cancer Research</i> , 2013 , 19, 6967-75	12.9	49
296	Nucleotide excision repair pathway genes and oral premalignant lesions. <i>Clinical Cancer Research</i> , 2007 , 13, 3753-8	12.9	49
295	Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study. <i>Lancet, The</i> , 2005 , 366, 1359-66	4.0	49
294	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1449-1459	8.9	49
293	Adaptive designs for identifying optimal biological dose for molecularly targeted agents. <i>Clinical Trials</i> , 2014 , 11, 319-327	2.2	48
292	Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. <i>Cancer Research</i> , 2011 , 71, 5512-21	10.1	48
291	Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019 , 30, 1521-1530	10.3	47
290	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3638-3651	2.2	47
289	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1021-1031	8.9	46
288	Controlled multi-arm platform design using predictive probability. <i>Statistical Methods in Medical Research</i> , 2018 , 27, 65-78	2.3	46
287	Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. <i>Cancer Research</i> , 2009 , 69, 7439-48	10.1	46
286	Percutaneous nephrostomy tube placement: an outpatient procedure?. <i>Radiology</i> , 1991 , 179, 843-7	20.5	46
285	New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. <i>Cancer Prevention Research</i> , 2015 , 8, 1027-35	3.2	45
284	Unique molecular landscapes in cancer: implications for individualized, curated drug combinations. <i>Cancer Research</i> , 2014 , 74, 7181-4	10.1	45
283	Epidemiology of head and neck squamous cell cancer among HIV-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 65, 603-10	3.1	45
282	MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. <i>Carcinogenesis</i> , 2010 , 31, 2118-23	4.6	45

281	Worth adapting? Revisiting the usefulness of outcome-adaptive randomization. <i>Clinical Cancer Research</i> , 2012 , 18, 4498-507	12.9	45
280	Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. <i>Clinical Cancer Research</i> , 2012 , 18, 3705-13	12.9	45
279	Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. <i>Clinical Cancer Research</i> , 2006 , 12, 2178-84	12.9	45
278	Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 1257-63	9.7	45
277	Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. <i>Urological Research</i> , 1999 , 27, 362-7		45
276	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. <i>Cancer</i> , 2016 , 122, 534-45	6.4	45
275	Phase II trial design with Bayesian adaptive randomization and predictive probability. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2012 , 61, 219-35	1.5	44
274	Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 317-24	4	44
273	Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. <i>Cancer</i> , 1994 , 74, 2908-17	6.4	44
272	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. <i>Nature Communications</i> , 2019 , 10, 2978	17.4	43
271	Biological activity of celecoxib in the bronchial epithelium of current and former smokers. <i>Cancer Prevention Research</i> , 2010 , 3, 148-59	3.2	43
270	Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. <i>Cancer Prevention Research</i> , 2009 , 2, 702-11	3.2	43
269	Fenretinide activity in retinoid-resistant oral leukoplakia. <i>Clinical Cancer Research</i> , 2006 , 12, 3109-14	12.9	43
268	Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. <i>Cancer Research</i> , 2006 , 66, 11194-206	10.1	43
267	Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. <i>Oncogene</i> , 2002 , 21, 8206-19	9.2	42
266	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5489-5501	12.9	41
265	JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2234-2245	6.1	41
264	Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. <i>Carcinogenesis</i> , 2006 , 27, 2034-7	4.6	41

263	Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. <i>Clinical Cancer Research</i> , 2007 , 13, 6532-9	12.9	41
262	A generalized response surface model with varying relative potency for assessing drug interaction. <i>Biometrics</i> , 2006 , 62, 986-95	1.8	41
261	A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	40
260	The BATTLE to personalize lung cancer prevention through reverse migration. <i>Cancer Prevention Research</i> , 2011 , 4, 962-72	3.2	40
259	CR represents an early index of potential long survival in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2010 , 45, 498-504	4.4	40
258	Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 1755-63	6.1	40
257	The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. <i>Annals of Oncology</i> , 2012 , 23, 78-85	10.3	40
256	Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 69-73	9.7	40
255	Accrual strategies for phase I trials with delayed patient outcome. <i>Statistics in Medicine</i> , 1999 , 18, 1155-69	6.3	40
254	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 779-791	8.9	39
253	Cyclin D1 and cancer development in laryngeal premalignancy patients. <i>Cancer Prevention Research</i> , 2009 , 2, 14-21	3.2	39
252	Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. <i>Oncotarget</i> , 2015 , 6, 18707-14	3.3	38
251	G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1747-1754	8.9	38
250	Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. <i>Annals of Oncology</i> , 1997 , 8, 85-91	10.3	38
249	High-dose fenretinide in oral leukoplakia. <i>Cancer Prevention Research</i> , 2009 , 2, 22-6	3.2	37
248	Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. <i>Journal of Molecular Diagnostics</i> , 2004 , 6, 180-90	5.1	37
247	VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 3849-61	12.9	36
246	A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. <i>Cancer Prevention Research</i> , 2011 , 4, 1580-9	3.2	36

245	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. <i>Modern Pathology</i> , 2018 , 31, 947-955	9.8	35
244	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2857-63	6.1	35
243	Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1976-82	2.2	35
242	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 892-901	12.9	34
241	Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. <i>Cancer</i> , 2012 , 118, 3993-4003	6.4	34
240	Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. <i>Cancer Prevention Research</i> , 2011 , 4, 185-93	3.2	34
239	The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. <i>Cancer Letters</i> , 2006 , 239, 136-43	9.9	34
238	Jaw pain and stiffness levels after repeated maximum voluntary clenching. <i>Journal of Dental Research</i> , 1989 , 68, 69-71	8.1	34
237	An overview of the design and conduct of the BATTLE trials. <i>Chinese Clinical Oncology</i> , 2015 , 4, 33	2.3	33
236	Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. <i>Cancer Research</i> , 2006 , 66, 2893-903	10.1	32
235	GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. <i>Cancer Research</i> , 2002 , 62, 1178-83	10.1	32
234	Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	31
233	A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. <i>Cancer</i> , 2009 , 115, 1713-22	6.4	31
232	Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. <i>Journal of Clinical Oncology</i> , 2001 , 19, 1493-500	2.2	31
231	Micronuclei, a biomarker for chemoprevention trials: results of a randomized study in oral pre-malignancy. <i>International Journal of Cancer</i> , 1994 , 59, 457-9	7.5	31
230	Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. <i>Molecular Cancer</i> , 2015 , 14, 113	42.1	30
229	Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. <i>Annals of Oncology</i> , 2014 , 25, 1184-92	10.3	30
228	Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction. <i>Statistics in Biopharmaceutical Research</i> , 2009 , 1, 4-17	1.2	30

227	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1376-1387	8.9	29
226	Receptor tyrosine kinase EphA5 is a functional molecular target in human lung cancer. <i>Journal of Biological Chemistry</i> , 2015 , 290, 7345-59	5.4	29
225	Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. <i>Cancer Prevention Research</i> , 2013 , 6, 8-17	3.2	29
224	Tetranucleotide microsatellite instability in surgical margins for prediction of local recurrence of head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 4022-8	12.9	29
223	The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. <i>Cancer</i> , 2002 , 95, 340-53	6.4	29
222	Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1911-20	2.2	29
221	Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 243-5	9.7	29
220	A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. <i>Oncologist</i> , 2014 , 19, 1040-1	5.7	28
219	Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1112-21	6.1	28
218	KISS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2011 , 30, 3163-73	9.2	28
217	The ISG15-specific protease USP18 regulates stability of PTEN. <i>Oncotarget</i> , 2017 , 8, 3-14	3.3	28
216	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8 Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. <i>Clinical Cancer Research</i> , 2020 , 26, 3211-3219	12.9	28
215	Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. <i>Cancer Research</i> , 2002 , 62, 2813-8	10.1	28
214	BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. <i>Statistics in Medicine</i> , 2017 , 36, 3302-3314	2.3	27
213	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. <i>Clinical Lung Cancer</i> , 2020 , 21, 341-348	4.9	27
212	Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. <i>Cancer</i> , 2013 , 119, 4277-83	6.4	27
211	Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. <i>Clinical Lung Cancer</i> , 2006 , 7, 326-31	4.9	27
210	Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 3175-84	6.1	26

209	Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 1946-54	12.9	26
208	Canadian Optically-guided approach for Oral Lesions Surgical (COOLS) trial: study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2011 , 11, 462	4.8	26
207	Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR- β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2011 , 12, 369-74	4.9	26
206	Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. <i>Clinical Cancer Research</i> , 2010 , 16, 34-44	12.9	26
205	The cost of prostate cancer chemoprevention: a decision analysis model. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1485-9	4	26
204	A semiparametric response surface model for assessing drug interaction. <i>Biometrics</i> , 2008 , 64, 396-405	1.8	25
203	Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. <i>Cancer</i> , 2005 , 103, 952-9	6.4	25
202	Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. <i>Clinical Lung Cancer</i> , 2014 , 15, 197-201	4.9	24
201	Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. <i>European Journal of Cancer</i> , 2008 , 44, 1603-11	7.5	24
200	Antibiotic prophylaxis for dental patients with joint prostheses? A decision analysis. <i>International Journal of Technology Assessment in Health Care</i> , 1990 , 6, 569-87	1.8	24
199	A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. <i>Statistics in Medicine</i> , 2019 , 38, 5299-5316	2.3	23
198	Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. <i>Contemporary Clinical Trials</i> , 2013 , 36, 642-50	2.3	23
197	CD147 and Ki-67 overexpression confers poor prognosis in squamous cell carcinoma of oral tongue: a tissue microarray study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015 , 119, 553-65	2.65	22
196	Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 2104-11	8.9	22
195	A Better Confidence Interval for Kappa (K) on Measuring Agreement between Two Raters with Binary Outcomes. <i>Journal of Computational and Graphical Statistics</i> , 1994 , 3, 301-321	1.4	22
194	Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. <i>Clinical Cancer Research</i> , 2017 , 23, 1414-1421	12.9	21
193	Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus. <i>Cancer Prevention Research</i> , 2015 , 8, 1131-7	3.2	21
192	Demystify statistical significance--time to move on from the p value to bayesian analysis. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 2-3	9.7	21

191	Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 826-94	21
190	Electronic thermography of normal facial structures: a pilot study. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1989 , 68, 346-51	21
189	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. <i>Seminars in Radiation Oncology</i> , 2018 , 28, 108-113	5.5 20
188	Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. <i>Carcinogenesis</i> , 2010 , 31, 1755-61	4.6 20
187	Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 78, 667-74	4 20
186	IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. <i>BMC Medical Research Methodology</i> , 2021 , 21, 111	4.7 20
185	drexplorer: A tool to explore dose-response relationships and drug-drug interactions. <i>Bioinformatics</i> , 2015 , 31, 1692-4	7.2 19
184	Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2014 , 15, 213-21	4.9 19
183	Comparison of multispectral wide-field optical imaging modalities to maximize image contrast for objective discrimination of oral neoplasia. <i>Journal of Biomedical Optics</i> , 2010 , 15, 066017	3.5 19
182	Retinoic acid receptor beta and telomerase catalytic subunit expression in bronchial epithelium of heavy smokers. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 165-8	9.7 19
181	Jaw pain and tenderness levels during and after repeated sustained maximum voluntary protrusion. <i>Pain</i> , 1991 , 45, 17-22	8 19
180	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 14139-52	3.3 19
179	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. <i>Clinical Lung Cancer</i> , 2019 , 20, 30-36.e3	4.9 19
178	AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. <i>Cancer Prevention Research</i> , 2018 , 11, 735-778	3.2 19
177	Inference and Decision Making for 21st-Century Drug Development and Approval. <i>American Statistician</i> , 2019 , 73, 319-327	5 18
176	Commentary on Hey and Kimmelman. <i>Clinical Trials</i> , 2015 , 12, 110-2	2.2 18
175	Membrane carbonic anhydrase IX expression and relapse risk in resected stage I-II non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 675-84	8.9 18
174	Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. <i>Cancer</i> , 2009 , 115, 1498-506	6.4 18

173	Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020 , 101, 104523	4.4	18
172	A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. <i>PLoS ONE</i> , 2009 , 4, e6274	3.7	17
171	Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. <i>Endocrinology</i> , 2011 , 152, 2164-73	4.8	17
170	Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. <i>Cancer</i> , 2008 , 113, 2488-95	6.4	17
169	Second trimester maternal serum pregnancy specific beta-1 glycoprotein (SP-1) levels in normal and Down syndrome pregnancies. <i>American Journal of Medical Genetics Part A</i> , 1990 , 37, 114-8		17
168	Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. <i>Clinical Cancer Research</i> , 2003 , 9, 2400-5	12.9	17
167	Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. <i>Statistics in Biosciences</i> , 2016 , 8, 99-128	1.5	16
166	Comparison of Bayesian Sample Size Criteria: ACC, ALC, and WOC. <i>Journal of Statistical Planning and Inference</i> , 2009 , 139, 4111-4122	0.8	16
165	Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1645-52	8.9	16
164	Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. <i>Clinical Cancer Research</i> , 2004 , 10, 5554-7	12.9	16
163	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. <i>Nature Communications</i> , 2021 , 12, 2722	17.4	16
162	Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. <i>Journal of the National Cancer Institute</i> , 2018 , 110,	9.7	15
161	Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2018 , 82, 83-90	4.4	15
160	Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology study. <i>Carcinogenesis</i> , 2014 , 35, 1760-4	4.6	15
159	Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1603-12	9.7	15
158	Design considerations for efficient prostate cancer chemoprevention trials. <i>Urology</i> , 2001 , 57, 205-12	1.6	15
157	The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. <i>Nature Communications</i> , 2016 , 7, 12961	17.4	15
156	High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. <i>Molecular Cancer Research</i> , 2017 , 15, 179-188	6.6	14

155	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 67-77	4.4	14
154	A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials. <i>Statistics in Medicine</i> , 2017 , 36, 27-42	2.3	14
153	Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 658-61	8.9	14
152	Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. <i>Cancer</i> , 2010 , 116, 2401-8	6.4	14
151	Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	14
150	Multimomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. <i>Genome Biology</i> , 2020 , 21, 271	18.3	13
149	Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity. <i>American Journal of Pathology</i> , 2016 , 186, 2162-2170	5.8	13
148	Cotargeting cyclin D1 starts a new chapter in lung cancer prevention and therapy. <i>Cancer Prevention Research</i> , 2011 , 4, 779-82	3.2	13
147	Uniform power method for sample size calculation in historical control studies with binary response. <i>Contemporary Clinical Trials</i> , 2001 , 22, 390-400		13
146	Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6008-6008	2.2	13
145	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer 2021 , 9,		13
144	Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. <i>Cancer</i> , 2018 , 124, 84-94	6.4	12
143	A Bayesian decision-theoretic sequential response-adaptive randomization design. <i>Statistics in Medicine</i> , 2013 , 32, 1975-94	2.3	12
142	Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 16746-56	3.3	12
141	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. <i>Clinical Cancer Research</i> , 2020 , 26, 5477-5486	12.9	12
140	Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2019 , 30, 471-477	10.3	12
139	Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. <i>Clinical Cancer Research</i> , 2021 , 27, 852-864	12.9	12
138	Simulation study for evaluating the performance of response-adaptive randomization. <i>Contemporary Clinical Trials</i> , 2015 , 40, 15-25	2.3	11

137	A Randomized Multicenter Phase II Study of Docosahexaenoic Acid in Patients with a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease. <i>Cancer Prevention Research</i> , 2018 , 11, 203-214	3.2	11
136	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 246-257	8.9	11
135	Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019 , 158, 911-919.e6	1.5	11
134	Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 770-777	4	11
133	Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. <i>Melanoma Research</i> , 1998 , 8, 149-55	3.3	11
132	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 601-609	8.9	11
131	F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 1519-1534	7.4	11
130	Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges. <i>Therapeutic Innovation and Regulatory Science</i> , 2014 , 48, 20-30	1.2	10
129	Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer. <i>International Journal of Oncology</i> , 2012 , 41, 1798-808	4.4	10
128	A simulation study for comparing testing statistics in response-adaptive randomization. <i>BMC Medical Research Methodology</i> , 2010 , 10, 48	4.7	10
127	Effects of 9-cis-retinoic acid on the insulin-like growth factor axis in former smokers. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4439-49	2.2	10
126	Extensions and Applications of Event Charts. <i>American Statistician</i> , 2000 , 54, 63-70	5	10
125	Deletion in poly(ADP-ribose)polymerase pseudogene and lung cancer risk. <i>Carcinogenesis</i> , 1998 , 19, 93-84.6	4.6	10
124	Anticlastogenic effects of 13-cis-retinoic acid in vitro. <i>European Journal of Cancer</i> , 1992 , 29A, 137-40	7.5	10
123	Racial Differences in 20-Year Cardiovascular Mortality Risk Among Childhood and Young Adult Cancer Survivors. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017 , 6, 414-421	2.2	10
122	Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. <i>Gut</i> , 2021 , 70, 555-566	19.2	10
121	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 3525-3536	12.9	9
120	Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. <i>Annals of Diagnostic Pathology</i> , 2014 , 18, 140-5	2.2	9

119	Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion. <i>Clinical Lung Cancer</i> , 2014 , 15, 379-86	4.9	9
118	Mortality in the randomized, controlled lung intergroup trial of isotretinoin. <i>Cancer Prevention Research</i> , 2010 , 3, 738-44	3.2	9
117	A Versatile One-Dimensional Distribution Plot: The BLiP Plot. <i>American Statistician</i> , 1997 , 51, 353-358	5	9
116	Likelihood-Weighted Confidence Intervals for the Difference of Two Binomial Proportions. <i>Biometrical Journal</i> , 1997 , 39, 387-407	1.5	9
115	/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. <i>Clinical Cancer Research</i> , 2021 , 27, 1720-1733	12.9	9
114	Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. <i>Oncotarget</i> , 2020 , 11, 600-618	3.3	9
113	Expression pattern of FGFR2, Grb2 and Plc β acts as a novel prognostic marker of recurrence recurrence-free survival in lung adenocarcinoma. <i>American Journal of Cancer Research</i> , 2015 , 5, 3135-48	4.4	9
112	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. <i>Nature Communications</i> , 2021 , 12, 687	17.4	9
111	Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes. <i>Biometrical Journal</i> , 2019 , 61, 1219-1231	1.5	8
110	Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. <i>Oncologist</i> , 2018 , 23, 526-e49	5.7	8
109	Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer. <i>Cancer Medicine</i> , 2019 , 8, 6383-6392	4.8	8
108	Polyamine measurements in the uterine cervix. <i>Journal of Cellular Biochemistry</i> , 1997 , 67, 125-132	4.7	8
107	Estimation of k for the poly-k test with application to animal carcinogenicity studies. <i>Statistics in Medicine</i> , 2003 , 22, 2619-36	2.3	8
106	Cell kinetic analysis of intact rat colonic crypts by confocal microscopy and immunofluorescence. <i>Gastroenterology</i> , 1996 , 111, 1493-500	13.3	8
105	A note on confidence limits for quartiles with right censored data. <i>Statistics in Medicine</i> , 1989 , 8, 1269-76.	6.3	8
104	Simultaneous non-parametric confidence intervals for survival probabilities from censored data. <i>Statistics in Medicine</i> , 1986 , 5, 653-62	2.3	8
103	Evaluation of lopamidol and diatrizoate in excretory urography: a double-blind clinical study. <i>American Journal of Roentgenology</i> , 1988 , 151, 523-7	5.4	8
102	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. <i>Genome Medicine</i> , 2021 , 13, 155	14.4	8

101	Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. <i>Infectious Agents and Cancer</i> , 2016 , 11, 21	3.5	8
100	Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. <i>Clinical Trials</i> , 2019 , 16, 645-656	2.2	7
99	Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints. <i>Statistical Methods in Medical Research</i> , 2020 , 29, 2717-2732	2.3	7
98	One step forward, two steps back. <i>Lancet Oncology</i> , 2014 , 15, 366-7	21.7	7
97	Accelerated approval and breakthrough therapy designation: oncology drug development on speed?. <i>Clinical Cancer Research</i> , 2013 , 19, 4305-8	12.9	7
96	Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 148-52	2.7	7
95	Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. <i>Scientific Reports</i> , 2021 , 11, 8511	4.9	7
94	BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 91-101	5.2	7
93	Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1625-1637	8.9	7
92	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. <i>Clinical Cancer Research</i> , 2017 , 23, 1407-1413	12.9	6
91	Use of a Targeted Exome Next-Generation Sequencing Panel Offers Therapeutic Opportunity and Clinical Benefit in a Subset of Patients With Advanced Cancers. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	6
90	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. <i>Oral Oncology</i> , 2018 , 77, 92-97	4.4	6
89	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. <i>EBioMedicine</i> , 2016 , 7, 85-93	8.8	6
88	Prediction-Oriented Marker Selection (PROMISE): With Application to High-Dimensional Regression. <i>Statistics in Biosciences</i> , 2017 , 9, 217-245	1.5	6
87	Outcome-adaptive randomization for a delayed outcome with a short-term predictor: imputation-based designs. <i>Statistics in Medicine</i> , 2014 , 33, 4029-42	2.3	6
86	Immune evasion in HPV head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	6
85	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021 , 12, 5045	17.4	6
84	Comparing three regularization methods to avoid extreme allocation probability in response-adaptive randomization. <i>Journal of Biopharmaceutical Statistics</i> , 2018 , 28, 309-319	1.3	5

83	Two-stage marker-stratified clinical trial design in the presence of biomarker misclassification. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2016 , 65, 585-601	1.5	5
82	Model diagnostic tests for selecting informative correlation structure in correlated data. <i>Biometrika</i> , 2008 , 95, 891-905	2	5
81	Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. <i>Clinical Lung Cancer</i> , 2003 , 5, 40-5	4.9	5
80	Re: Cancer chemoprevention: progress and promise. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 563-5	9.7	5
79	A Note on the Conditional Approach to Interval Estimation in the Calibration Problem. <i>Biometrics</i> , 1991 , 47, 1573	1.8	5
78	Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11019-11019	2.2	5
77	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 33995-34008	3.3	5
76	Adaptive clinical trial designs in oncology. <i>Chinese Clinical Oncology</i> , 2014 , 3,	2.3	5
75	Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. <i>Clinical Lung Cancer</i> , 2020 , 21, 384-388	4.9	5
74	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2021 , 22, e415-e424	4.9	5
73	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. <i>Chest</i> , 2021 , 159, 1256-1264	5.3	5
72	Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint. <i>Statistics in Biosciences</i> , 2018 , 10, 420-438	1.5	5
71	Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017 , 39, 2433-2443	4.2	4
70	A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. <i>Oncologist</i> , 2020 , 25, e1457-e1463	5.7	4
69	Reply to A. Levy et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 396	2.2	4
68	BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS8118-TPS8118	2.2	4
67	LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. <i>Annals of Thoracic Surgery</i> , 2020 , 110, 1131-1138	2.7	4
66	A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2019 , 48, 381-386	2.6	4

65	Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz010	4.6	3
64	Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 137-142	2.1	3
63	Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity Response. <i>Cancer Research</i> , 2011 , 71, 2794-2795	10.1	3
62	Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009 , 32, 15-9	2.7	3
61	9-cis-retinoic acid treatment increases serum concentrations of alpha-tocopherol in former smokers. <i>Clinical Cancer Research</i> , 2005 , 11, 2305-11	12.9	3
60	Extensions and Applications of Event Charts. <i>American Statistician</i> , 2000 , 54, 63	5	3
59	DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma. <i>Melanoma Research</i> , 1998 , 8, 145-8	3.3	3
58	A Phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. <i>Cancer</i> , 1999 , 86, 2291-2300	6.4	3
57	Calcium carbonate treatment of diarrhoea in intestinal bypass patients. <i>European Journal of Gastroenterology and Hepatology</i> , 1996 , 8, 559-62	2.2	3
56	Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer.. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022 ,	1.5	3
55	Incorporating historical information to improve phase I clinical trials. <i>Pharmaceutical Statistics</i> , 2021 , 20, 1017-1034	1	3
54	PI3-kinase pathway biomarkers in oral cancer and tumor immune cells. <i>Head and Neck</i> , 2019 , 41, 615-622	4.2	3
53	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. <i>Clinical Cancer Research</i> , 2021 , 27, 5072-5083	12.9	3
52	Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.. <i>Clinical Cancer Research</i> , 2022 , 28, 1345-1352	12.9	3
51	Monotonic single-index models to assess drug interactions. <i>Statistics in Medicine</i> , 2017 , 36, 655-670	2.3	2
50	Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2914-9	2.2	2
49	E _{max} model and interaction index for assessing drug interaction in combination studies. <i>Frontiers in Bioscience - Elite</i> , 2010 , 2, 582-601	1.6	2
48	Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. <i>Cancer Prevention Research</i> , 2010 , 3, 917-28	3.2	2

47	Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells. <i>Technology in Cancer Research and Treatment</i> , 2009 , 8, 163-76	2.7	2
46	Response: Re: Dose Escalation Methods in Phase I Cancer Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1733-1735	9.7	2
45	Rebuttal to the Response of Chou. <i>Cancer Research</i> , 2011 , 71, 2798-2800	10.1	2
44	On Recensoring for Censored Paired Data. <i>Journal of the American Statistical Association</i> , 1993 , 88, 104-118	11.8	2
43	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features		2
42	Applying Emax model and bivariate thin plate splines to assess drug interactions. <i>Frontiers in Bioscience - Elite</i> , 2010 , 2, 279-92	1.6	2
41	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2020 , 149, 33-40	5.9	2
40	Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase III Trial. <i>Advances in Therapy</i> , 2021 , 38, 4581-4591	4.1	2
39	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , 2021 , 27, 5049-5061	12.9	2
38	Novel Statistical Models for NSCLC Clinical Trials		1
37	Calibrating the prior distribution for a normal model with conjugate prior. <i>Journal of Statistical Computation and Simulation</i> , 2014 , 85, 3108-3128	0.9	1
36	Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method. <i>Contemporary Clinical Trials</i> , 2013 , 35, 170-8	2.3	1
35	On Recensoring for Censored Paired Data. <i>Journal of the American Statistical Association</i> , 1993 , 88, 104	2.8	1
34	Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9083-9083	2.2	1
33	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. <i>Nature Communications</i> , 2021 , 12, 6655	17.4	1
32	Evaluation of bias for outcome adaptive randomization designs with binary endpoints. <i>Statistics and Its Interface</i> , 2020 , 13, 287-315	0.4	1
31	Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials. <i>Emerging Topics in Statistics and Biostatistics</i> , 2020 , 395-426	0.2	1
30	Cancer Chemoprevention		1

29	Borrowing Strength and Borrowing Index for Bayesian Hierarchical Models. <i>Computational Statistics and Data Analysis</i> , 2020 , 144,	1.6	1
28	Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. <i>Cancer</i> , 2021 , 127, 2916-2925	6.4	1
27	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. <i>Clinical Cancer Research</i> , 2021 , 27, 5062-5071	12.9	1
26	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). <i>Clinical Cancer Research</i> , 2021 , 27, 5038-5048	12.9	1
25	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1965-1976	7.4	1
24	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. <i>Nature Communications</i> , 2021 , 12, 7081	17.4	1
23	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With or Alterations. <i>JTO Clinical and Research Reports</i> , 2021 , 2, 100237	1.4	0
22	An analysis of research biopsy core variability from over 5000 prospectively collected core samples. <i>Npj Precision Oncology</i> , 2021 , 5, 94	9.8	0
21	The Reality of Randomized Controlled Trials for Assessing the Benefit of Proton Therapy: Critically Examining the Intent-to-Treat Principle in the Presence of Insurance Denial. <i>Advances in Radiation Oncology</i> , 2021 , 6, 100635	3.3	0
20	The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials. <i>Pharmaceutical Statistics</i> , 2021 , 20, 1183-1199	1	0
19	Response adaptive randomization procedures in seamless phase II/III clinical trials. <i>Journal of Biopharmaceutical Statistics</i> , 2020 , 30, 3-17	1.3	0
18	A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials. <i>Statistics in Biopharmaceutical Research</i> , 2021 , 13, 147-155	1.2	0
17	Evaluating Bayesian adaptive randomization procedures with adaptive clip methods for multi-arm trials. <i>Statistical Methods in Medical Research</i> , 2021 , 30, 1273-1287	2.3	0
16	Principles and Reporting of Bayesian Trials. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 30-36	8.9	0
15	Bayesian Optimal Phase II Design for Randomized Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 1-19	1.2	0
14	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.. <i>Nature Communications</i> , 2022 , 13, 1797	17.4	0
13	Testing hypotheses about medical test accuracy: considerations for design and inference. <i>Journal of Applied Statistics</i> , 2015 , 42, 1106-1119	1	
12	Response. <i>Journal of the National Cancer Institute</i> , 2016 , 108, djw001	9.7	

- 11 RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. *Journal of the National Cancer Institute*, **2013**, 105, 833 9.7
- 10 A second-order semiparametric method for survival analysis, with application to an acquired immune deficiency syndrome clinical trial study. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2017**, 66, 833-846 1.5
- 9 A weight-adjusted Peto test when cause of death is not assigned. *Environmental and Ecological Statistics*, **2005**, 12, 95-113 2.2
- 8 ~~Carotene~~ may not prevent second head and neck cancer. *Evidence-based Oncology*, **2001**, 2, 200-201
- 7 Inferential Frameworks for Clinical Trials **2021**, 1-30
- 6 Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. *Clinical Cancer Research*, **2021**, 27, 5049-5061 12.9
- 5 Statistical Methods for Biomarker Analysis for Head and Neck Carcinogenesis and Prevention **2003**, 287-IV
- 4 Cancer Chemoprevention **2015**, 809-824.e4
- 3 Assessment of Drug Interactions with Repeated Measurements. *ICSA Book Series in Statistics*, **2017**, 277-291
- 2 Phase II Trials with Anticancer Agents **2011**, 141-161
- 1 A Collection of Statistical Methods for Precision Oncology.. *JCO Precision Oncology*, **2019**, 3, 1-3 3.6